Expression of surfactant protein D in airways of asthmatics and interleukin-13 modulation of surfactant protein D in human models of airway epithelium

Research

Jie Xu, Gurpreet K Singhera and Delbert R Dorscheid^*

Respiratory Research 2015, 16:26  doi:10.1186/s12931-015-0177-7

Abstract (provisional)

Background Surfactant protein D (SP-D), a pattern recognition molecule, has been shown to play roles in host defense such as opsonisation, aggregation of pathogens, and modulation of the inflammatory response. In light of infection-induced exacerbations and damage to the airway epithelium from inflammation, these functions of SP-D make it relevant in the development and pathogenesis of asthma.

H2-Eb1 expression is upregulated in the nasal mucosa of allergic rhinitis

Asian Pac J Allergy Immunol. 2014 Dec;32(4):308-15. doi: 10.12932/AP0478.32.4.2014.

Zhang Y1, Feng J, Sun J, Wang H, Zhang C, Liu H, Zhang H.

Abstract

BACKGROUND:

Allergic rhinitis (AR) is one of the most common allergic diseases. The results of recent studies of HLA-DRB1 suggest that HLA-DRB1 plays an important role in allergic disease.

Evaluation of patients’ expectations and benefits in the treatment of allergic rhinitis with a new tool: the patient benefit index – the benefica study

Research

Pascal Demoly^1*, Michel Aubier²³⁴, Frédéric de Blay⁵, François Wessel⁶, Pierre Clerson⁷ and Pascal Maigret⁸

Allergy, Asthma & Clinical Immunology 2015, 11:8  doi:10.1186/s13223-015-0073-1

Abstract (provisional)

Background Symptoms of allergic rhinitis (AR) have a detrimental effect on quality of life. The AR-Patient Benefit Index (AR-PBI), a specific self-assessment tool has been developed to assess treatment-related benefit in two separate sections: the Patient Needs Questionnaire (PNQ) which explores the patient’s expectations before treatment and the Patient Benefit Questionnaire (PBQ) which evaluates treatment benefit. For the PNQ, three dimensions summarized patients’ expectations: symptoms, social life and emotional state, thus covering a larger field than symptomatic relief.

Food allergy in the Netherlands: differences in clinical severity, causative foods, sensitization and DBPCFC between community and outpatients

Research

Thuy-My Le^1*, Els van Hoffen¹¹⁰, Ischa Kummeling¹², James Potts², Barbara K Ballmer-Weber³, Carla AFM Bruijnzeel-Koomen¹, Ans FM Lebens¹, Jonas Lidholm⁴, Titia M Lindner¹, Alan Mackie⁵, EN Clare Mills⁶, Ronald van Ree⁷, Stefan Vieths⁸, Montserrat Fernández-Rivas⁹, Peter G Burney² and André C Knulst¹

Clinical and Translational Allergy 2015, 5:8  doi:10.1186/s13601-015-0051-1

Abstract (provisional)

Background It is unknown whether food allergy (FA) in an unselected population is comparable to those from an outpatient clinic population.
Objective To discover if FA in a random sample from the Dutch community is comparable to that of outpatients.

Evaluation of a web-based asthma self-management system: a randomised controlled pilot trial

Research article

John M Wiecha^1*, William G Adams², Denis Rybin³, Maria Rizzodepaoli⁴, Jeremy Keller⁵and Jayanti M Clay⁶

BMC Pulmonary Medicine 2015, 15:17  doi:10.1186/s12890-015-0007-1

Abstract (provisional)

Background Asthma is the most common chronic condition of childhood and disproportionately affects inner-city minority children. Low rates of asthma preventer medication adherence is a major contributor to poor asthma control in these patients.

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids

Research

Christian Vogelberg^1*, Petra Moroni-Zentgraf², Migle Leonaviciute-Klimantaviciene³, Ralf Sigmund⁴, Eckard Hamelmann⁵, Michael Engel² and Stanley Szefler⁶

Respiratory Research 2015, 16:20  doi:10.1186/s12931-015-0175-9

Abstract

Background

A considerable number of children with asthma remain symptomatic despite treatment with inhaled corticosteroids, resulting in significant morbidity, reduced quality of life, increased healthcare costs and lost school days.

Insights and advances in chronic urticaria: a Canadian perspective

Review

Gordon Sussman^1*, Jacques Hébert², Wayne Gulliver³, Charles Lynde¹, Susan Waserman⁴, Amin Kanani⁵, Moshe Ben-Shoshan⁶, Spencer Horemans¹, Carly Barron¹,Stephen Betschel¹, William H Yang⁷, Jan Dutz⁵, Neil Shear¹, Gina Lacuesta⁸, Peter Vadas¹, Kenneth Kobayashi⁷, Hermenio Lima⁴ and F Estelle R Simons⁹

Allergy, Asthma & Clinical Immunology 2015, 11:7  doi:10.1186/s13223-015-0072-2

Abstract

In the past few years there have been significant advances which have changed the face of chronic urticaria. In this review, we aim to update physicians about clinically relevant advances in the classification, diagnosis and management of chronic urticaria that have occurred in recent years.

Effects of Nasal Corticosteroids on Boosts of Systemic Allergen-Specific IgE Production Induced by Nasal Allergen Exposure

OPEN ACCESS

PEER-REVIEWED

RESEARCH ARTICLE

Cornelia Egger, Christian Lupinek, Robin Ristl, Patrick Lemell, Friedrich Horak, Petra Zieglmayer, Susanne Spitzauer, Rudolf Valenta, Verena Niederberger

Published: February 23, 2015

DOI: 10.1371/journal.pone.0114991

Abstract

Background

Allergen exposure via the respiratory tract and in particular via the nasal mucosa boosts systemic allergen-specific IgE production. Intranasal corticosteroids (INCS) represent a first line treatment of allergic rhinitis but their effects on this boost of allergen-specific IgE production are unclear.